


**Certification under 37 CFR 1.8**

I hereby certify that this paper (along with any paper referred to as being associated herewith) is being electronically filed with the US Patent and Trademark Office on October 11, 2010.



Valerie Neymeyer-Tynkov

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No.:	09/890,371
Applicant:	Cevc, et al.
Examiner:	Bruce Hissong
Art Unit:	1646
Title:	Transnasal transport/immunization with highly adaptable carriers
Customer No.:	85965

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**


This letter and the attached form PTO/SB/08a are submitted after the issuance of an Official Action and before Allowance of the present application. No fees are believed to be due at this time. The Commissioner is authorized to charge Deposit Account No. 50-4939 in the event that any fees are deemed as due in this application, or to credit any overpayment.

Information submitted in this IDS is not meant to indicate that a search has been made, or that any given document is prior art in the context of the present invention.

This IDS is submitted within 3 months of issuance of a communication from the Japanese Patent Office. The IDS filed in this application on August 5, 2010 included documents cited by the Japanese Patent Office against a counterpart Japanese application. The English language summary of JP 8-183742 ("Ref. 3") submitted with the August 2010 IDS includes a statement that the present invention was published and disclosed by Aramaki. Aramaki discloses conventional liposomes (1:1 lipid:surfactant molar ratio), similar to those described in Examples 22-29 of the present application. This IDS is to disclose the Aramaki document, presumably cited by the Japanese Patent Office, and inadvertently omitted from the August 5, 2010 IDS.

Information disclosed herein and throughout prosecution of this application is believed to be complete and within the meaning of the duty to disclose information and the duty of good faith and candor imposed by the USPTO. In view of recent Federal Circuit caselaw, Applicant notes that no information that should be submitted in compliance with these duties has been intentionally omitted from this letter or from the accompanying Information Disclosure Statements and documents attached thereto. In the event that any material, non-cumulative information is deemed missing, it is noted that such omission was made without any intent to withhold information from the USPTO.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Valerie Neymeyer-Tynkov', is written over a horizontal line.

Valerie Neymeyer-Tynkov

Reg. No. 46,956

Neymeyer-Tynkov LLC

20 N. Clark St. Suite 600

Chicago, IL 60602

Phone: 312/965-1969